Clinicopathological analysis of methotrexate‐associated lymphoproliferative disorders: Comparison of diffuse large B‐cell lymphoma and classical Hodgkin lymphoma types
Open Access
- 23 May 2017
- journal article
- Published by Wiley in Cancer Science
- Vol. 108 (6) , 1271-1280
Abstract
Patients with rheumatoid arthritis often develop methotrexate‐associated lymphoproliferative disorders (MTX‐LPD) during MTX treatment. MTX‐LPD occasionally regresses spontaneously after simply discontinuing MTX treatment. In patients without spontaneous regression, additional chemotherapy is required to avoid disease progression. However, the differences between spontaneous and non‐spontaneous regression have yet to be elucidated. To clarify the factors important for spontaneous regression, we analyzed the clinicopathological features of 51 patients with rheumatoid arthritis who developed MTX‐LPD (diffuse large B‐cell lymphoma [DLBCL]‐type [n = 34] and classical Hodgkin lymphoma [CHL]‐type [n = 17]). We examined the interval from MTX discontinuation to the administration of additional chemotherapy. The majority of DLBCL‐type MTX‐LPD patients (81%) exhibited remission with MTX discontinuation alone. In contrast, the majority of CHL‐type MTX‐LPD patients (76%) required additional chemotherapy. This difference was statistically significant (P = 0.001). However, overall survival was not significantly different between DLBCL‐type and CHL‐type (91% vs 94%, respectively; P > 0.05). Thus, the morphological differences in the pathological findings of MTX‐LPD may be a factor for spontaneous or non‐spontaneous regression after discontinuation of MTX.Keywords
Funding Information
- Grant-in-Aid for Scientific Research (JP16K08666)
This publication has 19 references indexed in Scilit:
- Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritisLeukemia & Lymphoma, 2012
- Clinicopathologic correlations of diffuse large B‐cell lymphoma in rheumatoid arthritis patients treated with methotrexateCancer Science, 2010
- Immunomodulator agent-related lymphoproliferative disordersLaboratory Investigation, 2009
- Spontaneous remission of “methotrexate-associated lymphoproliferative disorders” after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literatureMedical Oncology, 2008
- Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitisRheumatology International, 2007
- Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese casesPathology - Research and Practice, 2006
- Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936Leukemia, 2003
- Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in FranceBlood, 2002
- Hodgkin's Disease and Lymphoproliferations Resembling Hodgkin's Disease in Patients Receiving Long-Term Low-Dose Methotrexate TherapyAmerican Journal of Surgical Pathology, 1996
- Epstein‐Barr virus‐associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin AArthritis & Rheumatism, 1995